Pfizer India (PFIZER) Q2 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 24/25 earnings summary
2 Sep, 2025Executive summary
Unaudited financial results for the quarter and half year ended September 30, 2024, were approved by the Board on October 28, 2024.
Financials prepared in accordance with Ind AS and reviewed by statutory auditors with no modifications.
Financial highlights
Revenue from operations for Q2 FY25 was ₹588.59 crore, up from ₹575.21 crore in Q2 FY24.
Net profit for Q2 FY25 stood at ₹158.35 crore, compared to ₹148.96 crore in Q2 FY24.
EPS for Q2 FY25 was ₹34.61, up from ₹32.56 in Q2 FY24.
Total income for H1 FY25 was ₹1,236.36 crore, up from ₹1,176.10 crore in H1 FY24.
Net profit for H1 FY25 was ₹309.06 crore, compared to ₹242.49 crore in H1 FY24.
Outlook and guidance
No forward-looking guidance or outlook was provided.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Pfizer India
- Q1 FY27 saw higher revenue and profit, with EPS up and strong equity despite exceptional costs.PFIZER
Q1 26/27 - FY26 revenue rose, net profit reached ₹722.43 crore, and a ₹75/share dividend is proposed.PFIZERQ4 25/26
- Net profit increased to ₹189.02 crore in Q3 FY26, with stable revenue and notable exceptional costs.PFIZERQ3 25/26
- Strong revenue and profit growth, with major dividends paid after asset sale gains.PFIZERQ2 25/26
- Strong financials, special dividend, and new launches mark a milestone 75th year.PFIZERAGM 2025
- Despite a tough year, strong brand growth and new launches signal a return to positive momentum.PFIZERAGM 2024
- Net profit and EPS increased year-over-year, with strong revenue growth and no audit issues.PFIZERQ1 24/25
- Revenue and profit increased year-over-year, with Thane property sale awaiting approval.PFIZERQ3 24/25
- FY25 net profit surged to Rs. 767.60 crore; Rs. 165/share total dividend recommended.PFIZERQ4 24/25